-16 EMP(2022.08)
🩸 LIKELY CASUALTIES (AI ESTIMATE):
- 🔴Clinical Research & Development (90%) ─ Reason: Failed trial directly eliminates immediate R&D need.
- 🔴Biostatistics / Data Management (80%) ─ Reason: Less data to crunch from halted pipeline.
- 🟡Project Management (Clinical/R&D) (75%) ─ Reason: Deprioritized program means reduced oversight necessity.
🤡 CORPORATE BS LEVEL:
85%













